Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine) Exclusion Criteria: * \- Patients with severe UC * Significant liver and kidney function abnormalities * Diabetic patients * Patients with Colorectal cancer patients * Patients taking rectal or systemic steroids * Patients on immunosuppressants or biological therapies * Addiction to alcohol and / or drugs * Known allergy to the studied medications * History of complete or partial colectomy. * Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction). * Patients with other inflammatory diseases and active infection. * Patients with stressful condition (COPD, morbid obesity). * Patients with liver disease. * Patients with thrombocytopenia and neutropenia. * Patients with any type of seizures (case report for mebendazole induced convulsion). * Patients with renal disease (case report for mebendazole induced nephrotoxicity). * Patients with coagulation disorders. * Patients on metronidazole (to avoid Stevens-Johnson syndrome). * Patients with hypersensitivity to mebendazole, albendazole or benzimidazole * Patients using antioxidants. * Pregnant and lactating females. * Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.